Royalty Pharma plc - Ordinary Shares - Class A Stock News

Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds, and so is its dividend payout.

A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.

The tech stock selloff in July surprised the market but not those investors who were paying attention.

Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.

Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on t...

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Exec...